Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer

Mitch Dowsett, Ian E. Smith, Steve R. Ebbs, J. Michael Dixon, Anthony Skene, Clive Griffith, Irene Boeddinghaus, Janine Salter, Simone Detre, Margaret Hills, Susan Ashley, Stephen Francis, Geraldine Walsh, Roger A'Hern, Carlos Arteaga, Aman Buzdar, James Ingle, Steven Come, Myles Brown

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine treatment of breast cancer has become increasingly popular, particularly using the nuclear marker Ki67, and holds the potential for prioritizing new treatments for full clinical development. There are weakly significant relationships between Ki67 change and clinical response that differ according to data handling. In the neoadjuvant Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen trial, suppression of Ki67 at both 2 and 12 weeks was greater with the aromatase inhibitor anastrozole than with either tamoxifen or the combination of anastrozole and tamoxifen. We report here that absolute values of Ki67 after 2 weeks were also significantly lower with anastrozole than with tamoxifen and the combination. This indicates that it may be possible to make such comparisons using surgical samples only. We argue that these changes in proliferation and concurrent changes in apoptosis may be expected to be more predictive of adjuvant benefit from endocrine therapy than clinical response.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume12
Issue number3 II
DOIs
StatePublished - Feb 1 2006

Fingerprint

Neoadjuvant Therapy
Tamoxifen
Apoptosis
Breast Neoplasms
Aromatase Inhibitors
Therapeutics
anastrozole

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., Griffith, C., ... Brown, M. (2006). Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clinical Cancer Research, 12(3 II). https://doi.org/10.1158/1078-0432.CCR-05-2127

Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. / Dowsett, Mitch; Smith, Ian E.; Ebbs, Steve R.; Dixon, J. Michael; Skene, Anthony; Griffith, Clive; Boeddinghaus, Irene; Salter, Janine; Detre, Simone; Hills, Margaret; Ashley, Susan; Francis, Stephen; Walsh, Geraldine; A'Hern, Roger; Arteaga, Carlos; Buzdar, Aman; Ingle, James; Come, Steven; Brown, Myles.

In: Clinical Cancer Research, Vol. 12, No. 3 II, 01.02.2006.

Research output: Contribution to journalArticle

Dowsett, M, Smith, IE, Ebbs, SR, Dixon, JM, Skene, A, Griffith, C, Boeddinghaus, I, Salter, J, Detre, S, Hills, M, Ashley, S, Francis, S, Walsh, G, A'Hern, R, Arteaga, C, Buzdar, A, Ingle, J, Come, S & Brown, M 2006, 'Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer', Clinical Cancer Research, vol. 12, no. 3 II. https://doi.org/10.1158/1078-0432.CCR-05-2127
Dowsett, Mitch ; Smith, Ian E. ; Ebbs, Steve R. ; Dixon, J. Michael ; Skene, Anthony ; Griffith, Clive ; Boeddinghaus, Irene ; Salter, Janine ; Detre, Simone ; Hills, Margaret ; Ashley, Susan ; Francis, Stephen ; Walsh, Geraldine ; A'Hern, Roger ; Arteaga, Carlos ; Buzdar, Aman ; Ingle, James ; Come, Steven ; Brown, Myles. / Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 3 II.
@article{e393de911dbb4710ac5cf856ef6f6a4b,
title = "Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer",
abstract = "The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine treatment of breast cancer has become increasingly popular, particularly using the nuclear marker Ki67, and holds the potential for prioritizing new treatments for full clinical development. There are weakly significant relationships between Ki67 change and clinical response that differ according to data handling. In the neoadjuvant Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen trial, suppression of Ki67 at both 2 and 12 weeks was greater with the aromatase inhibitor anastrozole than with either tamoxifen or the combination of anastrozole and tamoxifen. We report here that absolute values of Ki67 after 2 weeks were also significantly lower with anastrozole than with tamoxifen and the combination. This indicates that it may be possible to make such comparisons using surgical samples only. We argue that these changes in proliferation and concurrent changes in apoptosis may be expected to be more predictive of adjuvant benefit from endocrine therapy than clinical response.",
author = "Mitch Dowsett and Smith, {Ian E.} and Ebbs, {Steve R.} and Dixon, {J. Michael} and Anthony Skene and Clive Griffith and Irene Boeddinghaus and Janine Salter and Simone Detre and Margaret Hills and Susan Ashley and Stephen Francis and Geraldine Walsh and Roger A'Hern and Carlos Arteaga and Aman Buzdar and James Ingle and Steven Come and Myles Brown",
year = "2006",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-05-2127",
language = "English (US)",
volume = "12",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3 II",

}

TY - JOUR

T1 - Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer

AU - Dowsett, Mitch

AU - Smith, Ian E.

AU - Ebbs, Steve R.

AU - Dixon, J. Michael

AU - Skene, Anthony

AU - Griffith, Clive

AU - Boeddinghaus, Irene

AU - Salter, Janine

AU - Detre, Simone

AU - Hills, Margaret

AU - Ashley, Susan

AU - Francis, Stephen

AU - Walsh, Geraldine

AU - A'Hern, Roger

AU - Arteaga, Carlos

AU - Buzdar, Aman

AU - Ingle, James

AU - Come, Steven

AU - Brown, Myles

PY - 2006/2/1

Y1 - 2006/2/1

N2 - The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine treatment of breast cancer has become increasingly popular, particularly using the nuclear marker Ki67, and holds the potential for prioritizing new treatments for full clinical development. There are weakly significant relationships between Ki67 change and clinical response that differ according to data handling. In the neoadjuvant Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen trial, suppression of Ki67 at both 2 and 12 weeks was greater with the aromatase inhibitor anastrozole than with either tamoxifen or the combination of anastrozole and tamoxifen. We report here that absolute values of Ki67 after 2 weeks were also significantly lower with anastrozole than with tamoxifen and the combination. This indicates that it may be possible to make such comparisons using surgical samples only. We argue that these changes in proliferation and concurrent changes in apoptosis may be expected to be more predictive of adjuvant benefit from endocrine therapy than clinical response.

AB - The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine treatment of breast cancer has become increasingly popular, particularly using the nuclear marker Ki67, and holds the potential for prioritizing new treatments for full clinical development. There are weakly significant relationships between Ki67 change and clinical response that differ according to data handling. In the neoadjuvant Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen trial, suppression of Ki67 at both 2 and 12 weeks was greater with the aromatase inhibitor anastrozole than with either tamoxifen or the combination of anastrozole and tamoxifen. We report here that absolute values of Ki67 after 2 weeks were also significantly lower with anastrozole than with tamoxifen and the combination. This indicates that it may be possible to make such comparisons using surgical samples only. We argue that these changes in proliferation and concurrent changes in apoptosis may be expected to be more predictive of adjuvant benefit from endocrine therapy than clinical response.

UR - http://www.scopus.com/inward/record.url?scp=32944463744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944463744&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-2127

DO - 10.1158/1078-0432.CCR-05-2127

M3 - Article

C2 - 16467120

AN - SCOPUS:32944463744

VL - 12

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3 II

ER -